We suggest you to use analysis of Cadus fundamentals to see if markets are presently mispricing the company. We found twenty-five available fundamental indicators for Cadus Corporation which can be compared to its rivals. To make sure the equity is not overpriced, please confirm all Cadus fundamentals including its EBITDA as well as the relationship between Cash Flow from Operations and Retained Earnings . Please also double-check Cadus Corporation Price to Earning to validate the company can sustain itself down the road.Use Cadus to enhance returns of your portfolios. The stock experiences moderate upward volatility. Check odds of Cadus to be traded at $1.749 in 30 days
Cadus Company SummaryCadus competes with Regeneron Pharmaceuticals, Alexion Pharmaceuticals, Seattle Genetics, Sage Therapeutics, and N/A. Cadus Corporation engages in real estate acquisition, renovation, and construction activities in south Florida. Cadus Corporation was founded in 1992 and is based in New York, New York. Cadus operates under Biotechnology classification in USA and traded on OTC Market.
Cadus Cash Flow from Operations vs Book Value Per Share
Cadus Corporation is rated fourth overall in cash flow from operations category among related companies. It is rated below average in book value per share category among related companies .